Latest News & Features
Americas
Jazz Pharmaceuticals has opposed a US trademark applied for by a nutrition company to cover dietary supplements in class 5. 3 August 2018
Europe
Kim Nasmyth was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports. 3 August 2018
Americas
Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge. 2 August 2018
Big Pharma
The European Medicines Agency has announced plans to temporarily further scale back and suspend activities in order to cope with a more significant staff loss from the agency’s relocation than was originally expected. 2 August 2018
Americas
Sandy Macrae was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports. 2 August 2018
Americas
The US Court of Appeals for the Federal Circuit has ordered the Patent Trial and Appeal Board to reconsider its assessments in three inter partes reviews, in the wake of the US Supreme Court’s SAS Institute v Iancu decision. 1 August 2018
Americas
Generic drug maker Amneal has secured a finding of non-infringement in a Hatch-Waxman case over kidney disease drug Sensipar (cinacalcet hydrochloride). 1 August 2018
Americas
Morgan Lewis & Bockius has boosted its IP litigation team with the addition of seven partners from McDermott Will & Emery who have experience in the life sciences and technology industries. 1 August 2018
Biotechnology
Manuel Salmeron-Sanchez and Matthew Dalby were selected in the LSIPR 50 2018 publication for their influence on the life sciences industry. They featured in the business and innovation section, as LSIPR reports. 1 August 2018
Americas
US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations. 31 July 2018